Literature DB >> 17178899

Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult.

Janet K Hess-Wilson1, Hannah K Daly, William A Zagorski, Christopher P Montville, Karen E Knudsen.   

Abstract

Prostate cancer cells are dependent on androgen for growth and survival; as such, inhibition of androgen receptor (AR) activity is the first line of intervention for disseminated disease. Recently, specific cytotoxic agents have been shown to extend survival times in patients with advanced disease. Given the established ability of androgen to modify cell survival in prostate cancer cells, it is imperative to determine the effect of the hormonal environment on cytotoxic response. Here, we show that the response of prostate cancer cells to taxane-induced cell death is significantly enhanced by androgen stimulation in AR-positive, androgen-dependent prostate cancer cells. Similar results were observed on androgen-independent AR activation. By contrast, AR-positive yet androgen-independent or AR-negative cells were refractory to androgen influence on taxane function. The ability of androgen to potentiate taxane activity was dependent on its mitogenic capacity and was separable from overall AR activity, as coadministration of AR antagonists, G(1) cyclin-dependent kinase inhibitors, or high-dose (growth inhibitory) androgen nullified the proapoptotic function of androgen. Observed induction of cell death was attributed to caspase-dependent apoptosis and correlated with p53 activation. Combined, these data indicate that the cytotoxic effects of taxanes are substantially influenced by the hormonal environment and/or status of AR activity in prostate cancer cells and provide the foundation for refinement and optimization of cytotoxic intervention in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178899      PMCID: PMC4443485          DOI: 10.1158/0008-5472.CAN-06-2249

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

1.  Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.

Authors:  H Schatten; M Ripple; R Balczon; R Weindruch; A Chakrabarti; M Taylor; C N Hueser
Journal:  J Cell Biochem       Date:  2000-01       Impact factor: 4.429

2.  Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2006-05-01       Impact factor: 4.534

3.  E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2.

Authors:  T F Kowalik; J DeGregori; G Leone; L Jakoi; J R Nevins
Journal:  Cell Growth Differ       Date:  1998-02

4.  Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot.

Authors:  George H Yoo; Marie P Piechocki; John F Ensley; Tam Nguyen; Jeffery Oliver; Hong Meng; Danny Kewson; Terry Y Shibuya; Fulvio Lonardo; Michael A Tainsky
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

5.  Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP.

Authors:  Oskar W Rokhlin; Agshin F Taghiyev; Natalya V Guseva; Rebecca A Glover; Peter M Chumakov; Julia E Kravchenko; Michael B Cohen
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

6.  2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells.

Authors:  Carlos Perez-Stable
Journal:  Cancer Lett       Date:  2006-01-08       Impact factor: 8.679

Review 7.  Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents.

Authors:  R Agarwal
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

8.  Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes.

Authors:  A Hartel; A Didier; S E Ulbrich; M Wierer; H H D Meyer
Journal:  J Steroid Biochem Mol Biol       Date:  2004-10       Impact factor: 4.292

9.  Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.

Authors:  Barbara J Attardi; Janet Burgenson; Sheri A Hild; Jerry R Reel
Journal:  Mol Cell Endocrinol       Date:  2004-07-30       Impact factor: 4.102

Review 10.  Apoptosis in prostate cancer: progressive and therapeutic implications (Review).

Authors:  Gangduo Wang; Eddie Reed; Qingdi Q Li
Journal:  Int J Mol Med       Date:  2004-07       Impact factor: 4.101

View more
  11 in total

Review 1.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

2.  Novel role of androgens in mitochondrial fission and apoptosis.

Authors:  Vivek Choudhary; Ismail Kaddour-Djebbar; Vijayabaskar Lakshmikanthan; Taghreed Ghazaly; Gagan Singh Thangjam; Arun Sreekumar; Ronald W Lewis; Ian G Mills; Wendy B Bollag; M Vijay Kumar
Journal:  Mol Cancer Res       Date:  2011-07-01       Impact factor: 5.852

Review 3.  Androgen receptor coactivators that inhibit prostate cancer growth.

Authors:  Garrett Daniels; Ruchi Jha; Ying Shen; Susan K Logan; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2014-04-05

4.  Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

Authors:  Dana Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 5.  The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Authors:  Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-08-05       Impact factor: 5.678

6.  Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Authors:  Thomas Nelius; Stephanie Filleur; Alexander Yemelyanov; Irina Budunova; E Shroff; Yelena Mirochnik; Arin Aurora; Dorina Veliceasa; Wuhan Xiao; Zhou Wang; Olga V Volpert
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

Review 7.  Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Authors:  Karen E Knudsen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

8.  Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

Authors:  Ankur Sharma; Clay E S Comstock; Erik S Knudsen; Khanh H Cao; Janet K Hess-Wilson; Lisa M Morey; Jason Barrera; Karen E Knudsen
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

9.  Androgen receptor drives cellular senescence.

Authors:  Yelena Mirochnik; Dorina Veliceasa; Latanya Williams; Kelly Maxwell; Alexander Yemelyanov; Irina Budunova; Olga V Volpert
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

10.  Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.

Authors:  M J Schiewer; L M Morey; C J Burd; Y Liu; D E Merry; S-M Ho; K E Knudsen
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.